This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Duivenvoorden, W. C. M. Articles by Singh, G. Search for Related Content PubMed PubMed Citation Articles by Duivenvoorden, W. C. M. Articles by Singh, G.

Doxycycline Decreases Tumor Burden in a Bone Metastasis Model of Human Breast Cancer¹

Wilhelmina C. M. Duivenvoorden, Sneana Vukmirovi Popovi, árka Lhoták, Eric Seidlitz, Holger W. Hirte, Richard G. Tozer and Gurmit Singh²

Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ontario, L8V 5C2 Canada

Bone is one of the most frequent sites for metastasis in breast cancer patients,often resulting in significant clinical morbidity and mortality. Increased matrix metalloproteinase (MMP) activity of tumor cells correlates with a higher invasive and metastatic potential. Members of the tetracycline family of antibiotics, including doxycycline, have potential treatment value for bone metastasis; they inhibit cancer cell proliferation, and they are also potent MMP inhibitors and are highly osteotropic. Doxycycline treatment in an experimental bone metastasis mouse model of human breast cancer MDA-MB-231 cells resulted in a 70% reduction in total tumor burden when compared with placebo control animals. In tumor-bearing animals, the amount of doxycycline incorporated into the radius/ulna as assessed by ELISA was lower than in non-tumor-bearing animals. In doxycycline-treated mice, bone formation was significantly enhanced as determined by increased numbers of osteoblasts, osteoid surface, and volume, whereas a decrease in bone resorption was also observed. Doxycycline treatment may be beneficial for breast cancer patients with or at risk for osteolytic bone metastasis; it greatly reduces tumor burden and could also compensate for the increased bone resorption associated with the disease.

This article has been cited by other articles:

				A. A. El-Mabhouh, P. N. Nation, A. Kaddoura, and J. R. Mercer Unexpected Preferential Brain Metastases with a Human Breast Tumor Cell Line MDA-MB-231 in BALB/c Nude Mice Vet. Pathol., November 1, 2008; 45(6): 941 - 944. [Abstract] [Full Text] [PDF]

				S. D. Young, M. Whissell, J. C.S. Noble, P. O. Cano, P. G. Lopez, and C. J. Germond Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors. Clin. Cancer Res., May 15, 2006; 12(10): 3092 - 3098. [Abstract] [Full Text] [PDF]

				S. A. Rabbani, P. Khalili, A. Arakelian, H. Pizzi, G. Chen, and D. Goltzman Regulation of Parathyroid Hormone-Related Peptide by Estradiol: Effect on Tumor Growth and Metastasis in Vitro and in Vivo Endocrinology, July 1, 2005; 146(7): 2885 - 2894. [Abstract] [Full Text] [PDF]

				B. L. Eckhardt, B. S. Parker, R. K. van Laar, C. M. Restall, A. L. Natoli, M. D. Tavaria, K. L. Stanley, E. K. Sloan, J. M. Moseley, and R. L. Anderson Genomic Analysis of a Spontaneous Model of Breast Cancer Metastasis to Bone Reveals a Role for the Extracellular Matrix Mol. Cancer Res., January 1, 2005; 3(1): 1 - 13. [Abstract] [Full Text] [PDF]

				S. Fujioka, C. Schmidt, G. M. Sclabas, Z. Li, H. Pelicano, B. Peng, A. Yao, J. Niu, W. Zhang, D. B. Evans, et al. Stabilization of p53 Is a Novel Mechanism for Proapoptotic Function of NF-{kappa}B J. Biol. Chem., June 25, 2004; 279(26): 27549 - 27559. [Abstract] [Full Text] [PDF]

				O. Peyruchaud, C.-M. Serre, R. NicAmhlaoibh, P. Fournier, and P. Clezardin Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity J. Biol. Chem., November 14, 2003; 278(46): 45826 - 45832. [Abstract] [Full Text] [PDF]

				R. E. B. Seftor, E. A. Seftor, D. A. Kirschmann, and M. J. C. Hendrix Targeting the Tumor Microenvironment with Chemically Modified Tetracyclines: Inhibition of Laminin 5 {gamma}2 Chain Promigratory Fragments and Vasculogenic Mimicry Mol. Cancer Ther., November 1, 2002; 1(13): 1173 - 1179. [Abstract] [Full Text] [PDF]